Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | SNCA | P37840 | 4/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27440440 | 0.92 | APP (0.55) | APPSNCAENPP2MAPTTHRB | |
| SCHEMBL31050165 | 0.92 | APP (0.55) | APPSNCAENPP2MAPTTHRB | |
| SCHEMBL27440995 | 0.86 | APP (0.51) | APPSNCAENPP2MAPTTHRB | |
| SCHEMBL24163776 | 0.85 | APP (0.60) | APPSNCAENPP2MAPTTHRB | |
| SCHEMBL27440660 | 0.84 | APP (0.59) | APPSNCAENPP2MAPTTHRB | |
| SCHEMBL27440721 | 0.84 | APP (0.48) | APPSNCAENPP2MAPTLMNA | |
| SCHEMBL27440509 | 0.84 | SNCA (0.72) | APPSNCAENPP2THRBPTGDR2 | |
| SCHEMBL27440427 | 0.83 | APP (0.46) | APPSNCAENPP2SCDPTGDR2 | |
| SCHEMBL27440621 | 0.82 | PTGDR2 (0.49) | APPSNCAENPP2PTGDR2 | |
| SCHEMBL27440276 | 0.82 | ENPP2 (0.52) | APPSNCAENPP2MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145369-A1 | COMPOUNDS FOR TREATMENT OF HAIR LOSS | PELAGE PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |